Research
Together, we aim to shield patients from infection and improve the future of implantable medical devices.
SHIELD’s mission is to train 16 Doctoral Candidates (DCs) and equip them with a powerful combination of scientific expertise and transferable skills. The programme is designed to prepare the next generation of European researchers to lead innovation in biomaterials and infection-resistant medical devices. Through interdisciplinary research, clinical collaboration, and industry engagement, SHIELD aims to develop advanced strategies for preventing and treating implant-associated infections (IAI), while fostering long-term improvements in patient care and device performance.
Together, we aim to shield patients from infection and improve the future of implantable medical devices.
SHIELD Scientific Pillars
SHIELD DN is structured around three scientific pillars (areas of scientific focus) that drive research across three clinical areas: orthopaedics, otology and odontology, where infection control strategies are needed.
Scientific pillar 1: Regenerative medicine
Developing therapeutic strategies that support healing and tissue regeneration in the context of implant-associated infections.
Scientific pillar 2: Biomaterial science
Design and development of innovative biomaterials that minimise bacterial adhesion and biofilm formation on medical devices.
Scientific pillar 3: Translational research models
Bridging basic research with experimental proof-of-concept by utilising in vitro models to study bacterial behaviour and cellular host responses, advancing to in vivo models that mimic clinical scenarios of implant-associated infections.
Methodological Approaches
Each clinical area within SHIELD focuses on three core methodological approaches:
Methodological Approach 1:
Investigation of clinical aspects of IAI, conducting clinical studies within each area to gain scientific knowledge on its pathogenesis and optimise preventive and management practises for infection control.
Methodological Approach 2:
Antimicrobial strategies for implants, including research & development and gateway to industry:
2.1 Development of new coatings and surface modifications of implants that prevent bacterial adhesion and biofilm formation, thereby improving their durability and safety.
2.2 Exploring bacteriophage-based therapies to combat antibiotic-resistant bacterial infections in implants.
2.3 Functionalisation of implants with antimicrobial peptides to enhance implant integration and reduce infection risk.
Methodological Approach 3:
Development of preclinical models to study IAI mechanisms and provide proof-of-concept of the antimicrobial implants and therapies.